Abstract
Some residues in the cystic fibrosis transmembrane conductance regulator (CFTR) channel are the site of more than one CFTR variant that cause cystic fibrosis. Here, we investigated the function of S1159F and S1159P, two variants associated with different clinical phenotypes, which affect the same pore-lining residue in transmembrane segment 12 that are both strongly potentiated by ivacaftor when expressed in CFBE41o− bronchial epithelial cells. To study the single-channel behaviour of CFTR, we applied the patch-clamp technique to Chinese hamster ovary cells heterologously expressing CFTR variants incubated at 27°C to enhance channel residence at the plasma membrane. S1159F- and S1159P-CFTR formed Cl− channels activated by cAMP-dependent phosphorylation and gated by ATP that exhibited thermostability at 37°C. Both variants modestly reduced the single-channel conductance of CFTR. By severely attenuating channel gating, S1159F- and S1159P-CFTR reduced the open probability (Po) of wild-type CFTR by ≥75% at ATP (1 mM); S1159F-CFTR caused the greater decrease in Po consistent with its more severe clinical phenotype. Ivacaftor (10–100 nM) doubled the Po of both CFTR variants without restoring Po values to wild-type levels, but concomitantly, ivacaftor decreased current flow through open channels. For S1159F-CFTR, the reduction of current flow was marked at high (supersaturated) ivacaftor concentrations (0.5–1 μM) and voltage-independent, identifying an additional detrimental action of elevated ivacaftor concentrations. In conclusion, S1159F and S1159P are gating variants, which also affect CFTR processing and conduction, but not stability, necessitating the use of combinations of CFTR modulators to optimally restore their channel activity.
Original language | English |
---|---|
Pages (from-to) | 333-354 |
Number of pages | 22 |
Journal | Journal of Physiology |
Volume | 602 |
Issue number | 2 |
Early online date | 7 Jan 2024 |
DOIs | |
Publication status | Published - 15 Jan 2024 |
Bibliographical note
Funding Information:This work was supported by Cystic Fibrosis Foundation Therapeutics (grant no. SHEPPA14XX0) and the Cystic Fibrosis Trust (grant nos. SRC 005 and SRC 021) to D.N.S. and Cystic Fibrosis Foundation (grant no. CUTT13A1) and National Institute of Diabetes and Digestive and Kidney Diseases (grant no. R01 DK44003) to G.R.C. During part of this work, M.R. was supported by The Royal Golden Jubilee PhD Programme, co‐funded by the Thailand Research Fund and the UK Newton Fund (grant no. PHD/0105/2557). M.K.A.‐S. was the recipient of a scholarship and research funding from the Ministry of Higher Education, Research and Innovation of the Sultanate of Oman.
Publisher Copyright:
© 2024 The Authors. The Journal of Physiology © 2024 The Physiological Society.